Bausch & Lomb (BLCO) Cash from Investing Activities (2021 - 2026)
Bausch & Lomb's (BLCO) quarterly Cash from Investing Activities came in at -$87.0 million in Q2 2026, up 3.33% YoY from -$84.2 million in Q2 2025, and up 33.08% on a QoQ basis from -$130.0 million in Q1 2026.
Bausch & Lomb (BLCO) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Bausch & Lomb (BLCO) has 6 years of Cash from Investing Activities data on file, last reported at -$87.0 million in Q2 2026.
- Quarterly Cash from Investing Activities rose 3.33% year-over-year to -$87.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$466.0 million (up 4.31% YoY) and the FY2025 annual result came in at -$455.0 million, down 10.44% from the prior year.
- Cash from Investing Activities climbed to -$87.0 million in Q2 2026, from -$130.0 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$28.0 million in Q2 2023 to a low of -$1.9 billion in Q3 2023.
- A 5-year average of -$189.3 million and a median of -$88.5 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 3740.82% — and 2024, when it surged 94.9%.
- Tracing BLCO's Cash from Investing Activities over 5 years: stood at -$90.0 million in 2022, then slumped by 50.0% to -$135.0 million in 2023, then slumped by 37.04% to -$185.0 million in 2024, then decreased by 1.62% to -$188.0 million in 2025, then soared by 53.72% to -$87.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$87.0 million (Q2 2026), -$130.0 million (Q1 2026), and -$188.0 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -241.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -222.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -383.65 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -461.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -87.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -117.00 Mn |
| 10 | Bausch & Lomb | 6.14 Bn | 5.76 Bn | 867.00 Mn | -87.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.00 Mn |
| Jun 30, 2026 | -87.00 Mn |
| Mar 31, 2026 | -130.00 Mn |
| Mar 31, 2026 | -130.00 Mn |
| Dec 31, 2025 | -188.00 Mn |
| Dec 31, 2025 | -188.00 Mn |
| Sep 30, 2025 | -61.00 Mn |
| Sep 30, 2025 | -61.00 Mn |
| Jun 30, 2025 | -90.00 Mn |
| Jun 30, 2025 | -90.00 Mn |
| Mar 31, 2025 | -116.00 Mn |
| Mar 31, 2025 | -116.00 Mn |
| Dec 31, 2024 | -185.00 Mn |
| Dec 31, 2024 | -185.00 Mn |
| Sep 30, 2024 | -96.00 Mn |
| Sep 30, 2024 | -96.00 Mn |
| Jun 30, 2024 | -74.00 Mn |
| Jun 30, 2024 | -74.00 Mn |
| Mar 31, 2024 | -57.00 Mn |
| Mar 31, 2024 | -57.00 Mn |